NFASC and diffuse large B-cell lymphoma: The REMoDL-B trial showed subclass-specific responses to bortezomib addition, where the improved outcome of ABC-DLBCL is explained by the inhibition of the constitutive NF-ΚΒ signaling observed in this subclass [22].